Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Parma – page 15

219 clinical trials in Parma, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Parma at a glance
219
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

219 trials in Parma

Open in trial search

Plasma cell myeloma

Not recruiting

Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Haemophilia A without inhibitors

Not recruiting

Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Chronic kidney disease

Not recruiting

Study on the Effectiveness and Safety of Finerenone for Adults with Non-Diabetic Chronic Kidney Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Diabetic nephropathy

Not recruiting

Study on the Effectiveness and Safety of Finerenone and Empagliflozin in Adults with Chronic Kidney Disease and Type 2 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Bayer AG

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Parma

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and breast cancer treatments. Investigations include innovative immunotherapy approaches and targeted therapies for various cancer types.

  • Novel therapies for NSCLC patients
  • Triple-negative breast cancer treatments
  • Multiple myeloma management strategies

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Respiratory Medicine

Studies examining treatments for respiratory syncytial virus (RSV) infections in high-risk populations. Advanced research into preventive therapies and management strategies.

  • RSV prevention in infants
  • Respiratory support strategies
  • Critical care ventilation protocols

Focus on developing protective measures for vulnerable patient populations.

03 Transplant Medicine

Clinical trials evaluating new approaches to kidney transplantation and prevention of complications. Research on reducing delayed graft function and improving transplant outcomes.

  • Post-transplant care optimization
  • Graft function improvement
  • Novel immunosuppressive strategies

Emphasis on enhancing long-term transplant success rates.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.